Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Subjects with impaired glucose tolerance will be randomized to either rosiglitazone or
placebo for a 18 month period. The study will look at baseline, 12 month and 18 month data
for exercise tolerance, coronary artery calcification and diabetes indicators.